Pharmaceuticals

Remicade Biosimilar Industry Growth Insights: Revenue Forecast to 2030

February 18, 2026February 24, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the remicade biosimilar market from 2026–2035 with trusted insights from The Business Research Company

Starting from its 2026 valuation, what market size is the Remicade Biosimilar Market expected to reach by 2030?

The remicade biosimilar market has experienced substantial growth in its size over recent years. It is projected to expand from $4.89 billion in 2025 to $5.97 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 22.2%. Historically, this growth has been driven by the high cost burden of branded biologics, the patent expiry of remicade, the increasing prevalence of autoimmune diseases, government support for biosimilar approvals, and hospital-driven bulk procurement models.

The remicade biosimilar market is projected to experience substantial expansion in the coming years, forecast to reach $13.31 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 22.2%. Key drivers for this growth during the forecast period include the increasing need for economical biologic treatments, the expansion of biosimilar product pipelines, escalating healthcare spending in developing nations, greater acceptance among medical professionals and patients, and supportive reimbursement policies. Significant trends anticipated in this period encompass the wider embrace of budget-friendly biosimilars, growing confidence among prescribers in infliximab biosimilars, a broadening of therapeutic indications for autoimmune conditions, competitive pricing strategies coupled with tender-based purchasing, and deeper market penetration in nascent healthcare markets.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=11952&type=smp

What Drivers Are Driving Adoption Within The Remicade Biosimilar Market?

The increasing occurrence of autoimmune conditions is anticipated to fuel the expansion of the remicade biosimilar market. Autoimmune diseases are characterized by the immune system mistakenly attacking and damaging the body’s own tissues and organs. Remicade biosimilars serve as an effective therapeutic option for managing symptoms and reducing inflammation associated with these diseases. An illustration of this trend is provided by Arthritis Australia, an Australia-based charitable not-for-profit organisation advocating for people with arthritis and musculoskeletal conditions, which reported in February 2024 that by 2025, around 562,378 Australians are projected to have rheumatoid arthritis (RA), representing 14% of the total arthritis population. This figure is expected to climb by 33% to approximately 748,721 individuals by 2040. Consequently, the rising incidence of autoimmune diseases is a significant factor driving the growth of the remicade biosimilar market.

What Segments Are Included Within The Remicade Biosimilar Market?

The remicade biosimilar market covered in this report is segmented –

1) By Type: 100mg/10ml, 500mg/50ml

2) By Disease Indication: Ulcerative Colitis, Rheumatoid Arthritis, Ankylosing Spondylitis, Crohn’s Disease, Psoriatic Arthritis, Plaque Psoriasis

3) By Application: Blood Disorders, Oncology Diseases

Which Market Trends Are Opening Growth Opportunities In The Remicade Biosimilar Market?

Leading companies in the Remicade biosimilar market are concentrating on developing innovative solutions, such as subcutaneous formulations, to achieve a competitive edge. Subcutaneous Remicade formulations offer an alternative administration route for treating autoimmune diseases, enabling self-administration and potentially improving patient adherence to therapy. For example, in March 2024, Celltrion, a South Korea-based biopharmaceutical company, launched Zymfentra, a biosimilar to Remicade (infliximab) for $6,181.08 for two doses over four weeks. This product was approved by the FDA as the first subcutaneous infliximab formulation for maintaining therapy in adults with moderate-to-severe ulcerative colitis and Crohn’s disease. Eligible commercially insured patients can receive copay assistance of $5 per month, while uninsured or underinsured patients may obtain Zymfentra at no cost.

Who Are The Top-Performing Companies In The Remicade Biosimilar Market In Recent Years?

Major companies operating in the remicade biosimilar market are Novartis AG, Amgen Inc, Viatris Inc., Teva Pharmaceutical Industries Ltd., Biogen Inc., LG Chem Ltd., Nippon Kayaku Co. Ltd., Celltrion Inc., Nichi-iko Pharmaceutical Co. Ltd., Biocon Limited, Alvotech S.A., MabPharm Ltd., Genor Biopharma Co. Ltd, Shanghai Biomabs Pharmaceuticals Co. Ltd., Samsung Bioepis Co. Ltd., Biocad Biopharmaceutical Co, EPIRUS Biopharmaceuticals Inc., BioXpress Therapeutics SA, Mabion S.A

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/remicade-biosimilar-global-market-report

Which Region Currently Holds The Largest Share Of The Remicade Biosimilar Market?

Europe was the largest region in the remicade biosimilar market in 2025. The regions covered in the remicade biosimilar market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Remicade Biosimilar Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=11952&type=smp

Browse Through More Reports Similar to the Global Remicade Biosimilar Market 2026, By The Business Research Company

Remicade Biosimilar Market Report 2026

https://www.thebusinessresearchcompany.com/report/remicade-biosimilar-global-market-report

Biotechnology Reagents Market Report 2026

https://www.thebusinessresearchcompany.com/report/biotechnology-reagents-global-market-report

Bevacizumab Biosimilars Market Report 2026

https://www.thebusinessresearchcompany.com/report/bevacizumab-biosimilars-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795